Loading
Led KEYNOTE-006 and COMBI-v, the trials that made pembrolizumab and dabrafenib-trametinib standards in melanoma.
Caroline Robert was principal investigator of KEYNOTE-006, which showed pembrolizumab beats ipilimumab in advanced melanoma and established PD-1 monotherapy, of CheckMate 066 (nivolumab versus chemotherapy) and of COMBI-v (dabrafenib plus trametinib versus vemurafenib). She has led long-term follow-up analyses defining durable remission after stopping immunotherapy and heads dermato-oncology at Gustave Roussy.
Shares Advanced melanoma (unresectable stage III and stage IV), Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy, trialist.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tags melanoma, immunotherapy, trialist.
Shares Melanoma and the tags melanoma, immunotherapy, trialist.
Shares Advanced melanoma (unresectable stage III and stage IV), Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy.
Shares BRAF, Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy.
Shares Melanoma and the tags melanoma, immunotherapy, trialist.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tags immunotherapy, trialist.
Shares BRAF, Ipilimumab, Nivolumab, PD-1 and the tag melanoma.